These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
377 related articles for article (PubMed ID: 25344022)
1. Clinical impact of checkpoint inhibitors as novel cancer therapies. Shih K; Arkenau HT; Infante JR Drugs; 2014 Nov; 74(17):1993-2013. PubMed ID: 25344022 [TBL] [Abstract][Full Text] [Related]
2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
3. [Development of immune checkpoint inhibitors]. Kitano S Rinsho Ketsueki; 2017; 58(8):966-976. PubMed ID: 28883282 [TBL] [Abstract][Full Text] [Related]
4. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720 [TBL] [Abstract][Full Text] [Related]
5. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. Hahn AW; Gill DM; Pal SK; Agarwal N Immunotherapy; 2017 Jun; 9(8):681-692. PubMed ID: 28653573 [TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy. La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482 [TBL] [Abstract][Full Text] [Related]
7. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Dougall WC; Kurtulus S; Smyth MJ; Anderson AC Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Philips GK; Atkins M Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844 [TBL] [Abstract][Full Text] [Related]
10. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells. Kim N; Kim HS Front Immunol; 2018; 9():2041. PubMed ID: 30250471 [TBL] [Abstract][Full Text] [Related]
11. Clinical Development of Immune Checkpoint Inhibitors. Ito A; Kondo S; Tada K; Kitano S Biomed Res Int; 2015; 2015():605478. PubMed ID: 26161407 [TBL] [Abstract][Full Text] [Related]
12. Mechanistic and pharmacologic insights on immune checkpoint inhibitors. Sweis RF; Luke JJ Pharmacol Res; 2017 Jun; 120():1-9. PubMed ID: 28323141 [TBL] [Abstract][Full Text] [Related]
13. Checkpoint blocking antibodies in cancer immunotherapy. Kyi C; Postow MA FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671 [TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibition in ovarian cancer. Hamanishi J; Mandai M; Konishi I Int Immunol; 2016 Jul; 28(7):339-48. PubMed ID: 27055470 [TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Blockade in Breast Cancer Therapy. Bu X; Yao Y; Li X Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694 [TBL] [Abstract][Full Text] [Related]
16. The next generation of immunotherapy: keeping lung cancer in check. Somasundaram A; Burns TF J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399 [TBL] [Abstract][Full Text] [Related]
17. New insight in endocrine-related adverse events associated to immune checkpoint blockade. Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543 [TBL] [Abstract][Full Text] [Related]
18. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors. Langer CJ Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885 [TBL] [Abstract][Full Text] [Related]
19. [Next generation of anti-immune checkpoints antibodies]. Bonnefoy N; Olive D; Vanhove B Med Sci (Paris); 2019 Dec; 35(12):966-974. PubMed ID: 31903901 [TBL] [Abstract][Full Text] [Related]
20. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. Ma W; Gilligan BM; Yuan J; Li T J Hematol Oncol; 2016 May; 9(1):47. PubMed ID: 27234522 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]